University of California, Los Angeles, Department of Neurology, UCLA Multiple Sclerosis Program, 635 Charles E Young Drive South, Neuroscience Research Building 1, Room 479, Los Angeles, CA 90095, United States.
J Neuroimmunol. 2010 Feb 26;219(1-2):64-74. doi: 10.1016/j.jneuroim.2009.11.018. Epub 2009 Dec 14.
We studied the effects of combination treatment with an anti-inflammatory agent, interferon (IFN)-beta, and a putative neuroprotective agent, an estrogen receptor (ER)-beta ligand, during EAE. Combination treatment significantly attenuated EAE disease severity, preserved axonal densities in spinal cord, and reduced CNS inflammation. Combining ERbeta treatment with IFNbeta reduced IL-17, while it abrogated IFNbeta-mediated increases in Th1 and Th2 cytokines from splenocytes. Additionally, combination treatment reduced VLA-4 expression on CD4+ T cells, while it abrogated IFNbeta-mediated decreases in MMP-9. Our data demonstrate that combination treatments can result in complex effects that could not have been predicted based on monotherapy data alone.
我们研究了在 EAE 期间联合使用抗炎药干扰素 (IFN)-β和一种假定的神经保护剂雌激素受体 (ER)-β配体的治疗效果。联合治疗显著减轻了 EAE 的严重程度，保留了脊髓中的轴突密度，并减少了中枢神经系统的炎症。将 ERβ治疗与 IFNβ 联合使用可减少 IL-17，同时消除了 IFNβ 介导的脾细胞 Th1 和 Th2 细胞因子的增加。此外，联合治疗降低了 CD4+T 细胞上的 VLA-4 表达，同时消除了 IFNβ 介导的 MMP-9 减少。我们的数据表明，联合治疗可能会产生复杂的效果，这些效果不能仅根据单药治疗数据来预测。
